- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02374320
Exparel as a Nerve Block for Severe Hand Pain
April 24, 2024 updated by: Jose Soberon, MD
Chemical Sympathectomy Following Peripheral Nerve Block With Liposomal Bupivacaine
The purpose of this study is to investigate whether the use of the study drug (Exparel) is safe and effective for treating circulation problems and pain in the hand or fingers.
Study Overview
Status
Terminated
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
13
Phase
- Phase 2
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Louisiana
-
New Orleans, Louisiana, United States, 70121
- Ochsner Clinic Foundation
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- American Society of Anesthesiologists (ASA) status I-IV
Exclusion Criteria:
- True Allergy, not sensitivity to: local anesthetics, midazolam, fentanyl, propofol, ketamine
- Previous surgery or significant trauma involving the radial or ulnar arteries (previous history of angiography and intravascular catheter placement are permitted)
- Pregnancy
- Severe hepatic impairment
- Evidence of infection at or near the proposed needle insertion site
- Any sensorimotor deficit of the ipsilateral upper extremity, whether acute or chronic as determined by the PI and/or designee
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Exparel
20 mL liposomal bupivacaine injected once
|
injected as an axillary block
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Radial and Ulnar Arterial Diameter
Time Frame: 1 hour
|
Radial and ulnar artery diameter was measured at baseline and 60 min after with a Doppler ultrasound system.
A marker was used to indicate the site of initial transducer placement on the forearm to ensure that subsequent scans were performed at the same location.
|
1 hour
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Pain Measured by Numerical Rating Scale
Time Frame: 1 month
|
Numerical rating scale pain scores range from 0 (absence of pain) to 10 (worst pain imaginable)
|
1 month
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Jose Soberon, MD, Ochsner Health System
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
November 1, 2014
Primary Completion (Actual)
March 1, 2016
Study Completion (Actual)
March 1, 2016
Study Registration Dates
First Submitted
February 23, 2015
First Submitted That Met QC Criteria
February 26, 2015
First Posted (Estimated)
February 27, 2015
Study Record Updates
Last Update Posted (Actual)
May 21, 2024
Last Update Submitted That Met QC Criteria
April 24, 2024
Last Verified
April 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Digestive System Diseases
- Cardiovascular Diseases
- Metabolic Diseases
- Skin Diseases
- Arteriosclerosis
- Arterial Occlusive Diseases
- Gastrointestinal Diseases
- Connective Tissue Diseases
- Embolism and Thrombosis
- Atherosclerosis
- Skin Diseases, Vascular
- Thrombosis
- Esophageal Motility Disorders
- Deglutition Disorders
- Esophageal Diseases
- Calcium Metabolism Disorders
- Calcinosis
- Telangiectasis
- Scleroderma, Limited
- Livedoid Vasculopathy
- Vascular Diseases
- Peripheral Arterial Disease
- Peripheral Vascular Diseases
- Scleroderma, Systemic
- Scleroderma, Diffuse
- Raynaud Disease
- CREST Syndrome
- Physiological Effects of Drugs
- Central Nervous System Depressants
- Peripheral Nervous System Agents
- Sensory System Agents
- Anesthetics
- Anesthetics, Local
- Bupivacaine
Other Study ID Numbers
- 2014.155.C
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.